Abstract: [Problem] To provide a method for producing a colloidal crystal, wherein the method is easily controlled and is capable of dealing with a wide range of types of colloidal particle. [Solution] The method for producing a colloidal crystal in the present invention is characterized by comprising a preparation step of preparing a colloidal dispersion liquid, in which colloidal particles are dispersed in a liquid comprising an ionic surfactant and a colloidal crystal can be formed due to temperature changes, and a crystallization step of formation of a colloidal crystal by changing the temperature of the colloidal dispersion liquid from a temperature region in which the colloidal crystal is not formed to a temperature region in which the colloidal crystal is formed.

Abstract: In some embodiments, a device to measure a shape of cyclic variation of heart rate (CVHR) comprises a processor to detect CVHR from time series data of cardiac or pulse wave inter-beat interval, heart rate, or pulse rate; acquire at least one shape property index with respect to a waveform of the detected CVHR; and evaluate health risk based on the at least one shape property index. The CVHR appears periodically in the time series data. The at least one shape property index is selected from the group consisting of an amplitude of the CVHR (ACV), a slope, a ratio of the ACV to a duration, and an area. The health risk is inversely correlated with an intensity of a heart rate response determined from the at least one shape property index.

Abstract: [Object] Provided are a “eutectic colloidal crystal” which is an aggregate of plural kinds of colloidal crystals having different lattice constants, a solidified body of the eutectic colloidal crystal, and methods for producing them. [Resolution means] The eutectic colloidal crystal of the present invention contains two or more kinds of colloidal crystals composed of substantially monodispersed colloidal particles having different particle sizes. This eutectic colloidal crystal is obtained by providing a colloidal dispersion of two or more kinds of colloidal particles having different particle sizes, and a polymer which will not substantially adsorb to the colloidal particles (the coefficient of variation in particle size of these colloidal particles is less than 20%) dissolved in a dispersion medium (dispersion preparation process), and allowing the colloidal dispersion to stand (eutectoid process).

Abstract: A wakefulness-maintenance apparatus applies a stimulus, which is not perceived to be unpleasant to most seated persons, to a seated person, and effectively maintaining the wakefulness of the seated person. After a control device provided to the wakefulness-maintenance apparatus stimulates the seated person using a first stimulus at a timing close to a human heartbeat, if an index showing the wakefulness of the seated person departs within a predetermined time from a standard indicating that the wakefulness has been maintained, the control device drives a stimulus device to stimulate the seated person using a second stimulus having a timing that differs from the first stimulus.

Abstract: The present invention is directed to developing a glycan markers capable of detecting a hepatic disease, and more specifically to developing a glycan marker indicating a hepatic disease-state. Furthermore, the present invention is also directed to developing a glycan marker capable of distinguishing hepatic disease-states with the progress of hepatocarcinoma. The present inventors identified, among the serum glycoproteins, glycopeptides and glycoproteins in which a glycan structure specifically changes due to a hepatic diseases including hepatocarcinoma and provide these as novel glycan markers (glycopeptide and glycoprotein) specific to hepatic disease-states.

Abstract: It becomes possible to stably deliver an inhaled particulate medicine to a targeted part for administration while reducing burdens on a patient. When supplying the particulate medicine into a body by an airflow, a multi-layer flow composed of a core airflow (A) and a clad airflow (B) outside the core airflow is used as the airflow. The medicine is dispersed in the core airflow (A) and velocity of the clad airflow (B) is set higher than that of the core airflow (A). The medicine dispersed in the core airflow (A) reaches the targeted part for administration while the medicine is protected by the clad airflow (B) without contacting a larynx and the like. A cross-sectional area of the airflow is set smaller than that of the larynx. The airflow is supplied to an upper side of the larynx.

Abstract: An alertness device includes a heart rate sensor configured to obtain an electrocardiographic signal of a person, a calculation unit configured to calculate the electrocardiographic signal obtained from the heart rate sensor, a waveform generation unit configured to generate an RRI waveform from an electrocardiographic waveform of the electrocardiographic signal, and a determination unit configured to determine the alertness of the person based on the electrocardiographic signal. The calculation unit replicates a same number of RRI waveforms as that of anchors, each anchor being a point where a certain RRI is shorter than an adjacent preceding RRI, moves the time axes of the replicated RRI waveforms such that the anchors of the replicated RRI waveforms are in phase with each other, and calculates a PRSA signal defined as an RRI average for each time axis. The determination unit determines the alertness based on the RRIs and the PRSA signals.

Abstract: A subgenomic replicon RNA (nucleic acid) having an excellent autonomously replicating ability and a fullgenomic replicon RNA (nucleic acid) having an excellent autonomously replicating ability and infectious HCV particle-producing ability, each derived from a novel HCV of genotype 1b, are provided. Particularly, a subgenomic replicon RNA (nucleic acid) and a fullgenomic replicon RNA (nucleic acid), each derived from an HCV genome of the NC1 strain which is a novel HCV genotype 1b isolated from a patient with acute severe hepatitis C, are provided.

Abstract: An object of the present invention is to provide a screening system that targets ion channels and has superior efficiency. The present invention provides a material for screening for compounds that act on a target ion channel, comprising cells which retain at least one first DNA encoding a voltage-dependent Na ion channel that has been inhibited from being inactivated, and in which a K ion channel has been activated so that a resting membrane potential becomes deeper in a negative direction.

Abstract: A subgenomic replicon RNA (nucleic acid) having an excellent autonomously replicating ability and a fullgenomic replicon RNA (nucleic acid) having an excellent autonomously replicating ability and infectious HCV particle-producing ability, each derived from a novel HCV of genotype 1b, are provided. Particularly, a subgenomic replicon RNA (nucleic acid) and a fullgenomic replicon RNA (nucleic acid), each derived from an HCV genome of the NC1 strain which is a novel HCV genotype 1b isolated from a patient with acute severe hepatitis C, are provided.

Abstract: A pharmaceutical for preventing or treating a disorder accompanied by ocular angiogenesis and/or increased ocular vascular permeability, composed of a combination of an anti-VEGF agent, and a pyrrolo[1,2-a]pyrazine derivative represented by a general formula (I): in the formula, R1 and R2 are simultaneously or individually each a hydrogen atom, a halogen atom, a trifluoromethyl group, a lower alkyl group, a lower alkoxy group or a nitro group, and R3 is a hydrogen atom, a halogen atom or a lower alkyl group, or a pharmacologically acceptable salt thereof.

Abstract: [Problem] To provide a method for producing a colloidal crystal, wherein the method is easily controlled and is capable of dealing with a wide range of types of colloidal particle. [Solution] The method for producing a colloidal crystal in the present invention is characterized by comprising a preparation step of preparing a colloidal dispersion liquid, in which colloidal particles are dispersed in a liquid comprising an ionic surfactant and a colloidal crystal can be formed due to temperature changes, and a crystallization step of formation of a colloidal crystal by changing the temperature of the colloidal dispersion liquid from a temperature region in which the colloidal crystal is not formed to a temperature region in which the colloidal crystal is formed.

Abstract: An object of the present invention is to provide a screening system that targets ion channels and has superior efficiency. The present invention provides a material for screening for compounds that act on a target ion channel, comprising cells which retain at least one first DNA encoding a voltage-dependent Na ion channel that has been inhibited from being inactivated, and in which a K ion channel has been activated so that a resting membrane potential becomes deeper in a negative direction.

Abstract: It becomes possible to stably deliver an inhaled particulate medicine to a targeted part for administration while reducing burdens on a patient. When supplying the particulate medicine into a body by an airflow, a multi-layer flow composed of a core airflow (A) and a clad airflow (B) outside the core airflow is used as the airflow. The medicine is dispersed in the core airflow (A) and velocity of the clad airflow (B) is set higher than that of the core airflow (A). The medicine dispersed in the core airflow (A) reaches the targeted part for administration while the medicine is protected by the clad airflow (B) without contacting a larynx and the like. A cross-sectional area of the airflow is set smaller than that of the larynx. The airflow is supplied to an upper side of the larynx.

Abstract: An instrument for ultraviolet irradiation includes a plurality of light-shielding filters each having different transmittances for ultraviolet radiation emitted from a light source for irradiating the skin of a patient with ultraviolet radiation, and a support member for supporting the light-shielding filters.